Pathology Research Faculty
Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and leads a laboratory that studies the ENPP enzymes – a family of extracellular enzymes regulating hemostasis, bone mineralization, and vascular development. These studies have progressed to the development of biologic therapeutics for vascular calcification disorders.
My primary activities involve teaching students at Yale School of Medicine, with an emphasis on curriculum development and the application of new technologies for instruction.
José Costa, MD, FACP, is Professor Emeritus of Pathology at Yale University School of Medicine and Professeur Honoraire at the University of Lausanne Switzerland. Dr. Costa is an internationally renowned leader in the field of diagnostics of cancer and pathogenesis of tumor formation. Having contributed to the transition from opinion-based medicine to evidence-based diagnosis he is now making use of novel tools to practice integrative systems pathology, an approach that strives to enable a personalized, predictive and precise diagnosis.
Prior his transition to Emeritus status April first 2018 at the Yale School of Medicine, Dr Costa served in several positions of leadership that include: Chief of the Anatomical Pathology Branch at the Clinical Center, NIH Bethesda Md (1980-83); Director of the Institute of Pathology, University of Lausanne, Lausanne, Switzerland (1983-1993); President of the Board of Directors of the Centre Pluridisciplinaire d’Oncologie, Lausanne Switzerland (1985-1992); Director of Anatomical Pathology Yale New-Haven Hospital (1993-2007); and Deputy Director of the Yale Comprehensive Cancer Center (1995-2007). He is a sought after advisor to several academic, research and health organizations has served or currently serves as board member or advisor to several institutions including the ISREC (Swiss Cancer Research Institut); the Ludwig Institut Branch in Lausanne; the Deutsche Krebs Forshung Zenter (Heidelberg); the Institut of Molecular Pathology at Porto (Portugal); The Catalan Institut of Oncology [ICO] Barcelona, Spain; the Centro Nacional de Investigacion en Oncologia[CNIO] Madrid,Spain, the Instituto Carlos III, Madrid, Spain, the Center for Virtual Tumor Modeling (Harvard); the NIH Consensus Pannels and the NCI’s EDRN in Bethesda, MD, USA.
Throughout his career Dr. Costa has integrated advances in basic understanding of cancer to the clinical area of diagnosis, prognosis and early detection. He has contributed over 170 original publications to the technical literature, and is among a small group of investigators using evolutionary and ecological theory to predict tumor behavior. His laboratory investigates the micro-evolutionary dynamics involved in tumor formation and tumor progression using both experimental and theoretical modeling at the systems level. This work has identified novel and promising ways to detect early cancer and ways to follow the changes in tumors under therapy. Dr. Costa is co-inventor of two novel diagnostic technologies and has served in the oversight board of Yale’s Office of Cooperative Research. He has also been involved in the crafting of public-private joint ventures in Switzerland (IP-AMS Labs ), the early launching of Curagen Corporation (New Haven, CT ), the founding of Aureon Biosciences (Yonkers, NY ), VCN (Barcelona, Spain ), and PetaOmics (San Marcos, TX ).
The contributions of Dr Costa have been recognized by several awards including a Special Achievement Award from NIH, election as a Fellow to the American Association for the Advancement of Science (2003); the Gold Medal of the International Academy of Pathology and the Trueta Medal from the Catalan government for contributions to public health.
A firm believer in the dynamics coming from multi-disciplinarity and cooperation, Dr Costa continues to create an environment that will transform health care and set the standards for the 21st century. He is particularly interested in exploring synergies between academia, private industry, and governmental programs.
Karin Finberg received her B.S., M.D., and Ph.D. degrees from Yale. Her Ph.D. dissertation with Dr. Richard Lifton in the Department of Genetics focused on the genetic basis of an autosomal recessive disorder of systemic pH homeostasis, distal renal tubular acidosis with sensorineural deafness. After graduating from Yale, Karin completed residency training in Clinical Pathology at Massachusetts General Hospital and clinical fellowship training in the Harvard Medical School Molecular Genetic Pathology Training Program based at Brigham and Women’s Hospital. She then completed postdoctoral research training in the laboratory of Dr. Nancy Andrews, first at Children’s Hospital Boston and later at Duke University Medical Center, where she employed genetic study of patients with an inherited form of iron deficiency anemia to shed insight into mechanisms of systemic iron regulation. In her research laboratory at Yale, Karin continues to investigate mechanisms of iron balance through genetic study of patients with iron-related phenotypes and through characterization of genetically targeted mouse models. She also contributes to patient care as a molecular genetic pathologist in the Molecular Diagnostics Unit of the Department of Pathology.
Dr. Peter Gershkovich received his medical degree from the Altay State Medical Institute, Barnaul, Russia. After graduation, he remained in his alma mater, getting a prestigious position as an assistant professor the Department of Physiology where he developed strong interest in information technology and its practical applications for the computerized assessment of cardiac and respiratory function. After immigrating to the US at the end of 1993 and receiving Master’s degree in Health Administration from Suffolk University, Boston he worked as a professional programmer in the field of medicine for several years. In 2000 he was accepted into the Medical Informatics Fellowship at Yale Center for Medical Informatics where he continued learning software development focusing on genomic data analysis, automation of clinical guidelines, and information visualization.
Shortly after finishing the fellowship program, Dr. Gershkovich joined the Informatics team at Yale Medical School Pathology Department. He is currently a Research Scientist and the Director of Pathology Informatics at Yale Medical School.
Dr. Gershkovich has more than twenty years of experience in medical software development. Combining his knowledge of medicine and programming over the past fourteen years with Yale Medical School Pathology Department, Dr. Gershkovich has been studying methods of agile software development to rapidly close the functionality gaps that exist between emerging technologies and commercial Laboratory Information Systems (LIS). He developed a range of cutting-edge software applications that bridged research and clinical operations. Dr. Gershkovich remains interested in clinical information visualization, DNA sequencing analysis, NLP, and full-text search of clinical data.
My major interests are in diagnostic and experimental lung pathology.
I entered the MD-PhD program at Yale School of Medicine in 1979. My PhD was with Donal Murphy on a novel antigenic structure within the murine MHC. Upon graduation I trained in Anatomic Pathology under the supervision of Dr. Juan Rosai and simultaneously completed a post-doctoral fellowship with Richard Flavell, Chair of the section of Immunobiology, with a focus on T cell tolerance.
For many years, I worked on various murine models of inflammatory lung disease, ran a morphology core and a laboratory at West Haven VA. I now still consult on various experimental models of lung disease (both neoplastic and non-neoplastic) and work with collaborators using human tissues.
I am heavily involved in medical school curriculum development as Director of Medical Studies for Pathology, am on the curriculum committee and am Co-Director of one of the new master courses for the new (starting 2015) pre-clinical curriculum for YSM.
I have been Director of Anatomic Pathology at West Haven VA since 1994. I have been lead thoracic pathologist at Yale since 2004.
Dr. Hudnall is an AP/CP board certified hematopathologist with a special interest in lymphoproliferative disorders and the role of chronic imflammation and tumor-infiltrating lymphocytes and monocytes in tumor progression. Dr. Hudnall is also interested in the role of infectious agents in lymphoproliferative disorders, with a special interest in herpes viruses.
Dr. Hui is Professor in the Department of Pathology and Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. He received combined anatomic and clinical pathology residency training at Yale-New Haven Hospital in 2000, followed by Oncological Pathology Fellowship training at MSKCC. He joined the pathology faculty at Yale in 2001 and became full professor in 2013. Dr. Hui is a board certified surgical pathologist with clinical specialty areas including gynecologic pathology and molecular diagnostics. Currently, he is Director of Gynecologic Pathology Service, Clinical director of the Molecular Diagnostics Laboratory and Director of Gynecologic Pathology Fellowship Program.
Dr. Hui oversees a dynamic, high volume gynecologic pathology service at Yale. One of his long-term academic goals is to build an outstanding gynecological pathology program with emphasis on diagnostic tissue evaluation, oncological biomarker identification and clinical applications, and understanding the pathogenesis of various gynecological cancers. Dr. Hui has particular clinical expertise in the diagnostic workup of gestational trophoblastic disease. He serves on the editorial boards of International Journal of Gynecological Pathology, Human Pathology, American Journal of Clinical Pathology and Journal of Clinical Pathology. He has authored over 190 publications and written three pathology textbooks including Cytology and Surgical Pathology of Gynecologic Neoplasms, Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology, and Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic Pathology. Dr. Hui was a member of the consensus and editorial working group for the 2014 WHO Blue Book of tumor classifications of female reproductive organs and is the responsible author for the WHO classification of gestational trophoblastic disease. Dr. Hui serves on the Board of Directors of the International Society of Gynecological Pathologists (ISGyP) since 2015 and is currently treasurer of the society.
Michael Kashgarian is professor emeritus of and senior research scientist in pathology. He received his medical degree from Yale School of Medicine in 1958, completed his residency in pathology at the Yale-New Haven Medical Center in 1963, and completed a fellowship in laboratory medicine at Yale-New Haven Hospital in 1964. While on the Yale faculty he established a diagnostic renal pathology and electron microscopy laboratory that bears his name. He was also a pioneer in understanding the process of organ rejection. Although Kashgarian has retired, he continues to be active in the diagnosis of renal and cardiac biopsies.
Samuel G. Katz graduated with a combined B.S./M.S. from Yale University in 1995. He then pursued dual M.D., Ph.D. training in the Health Sciences & Technology (HST) program jointly administered by MIT and Harvard. His Ph.D. thesis with Stuart H. Orkin focused on the transcriptional regulation of hematopoiesis. Sam then completed a residency in pathology and fellowship in hematopathology at Brigham and Women’s Hospital. He performed his post-doctoral studies on apoptosis with Loren D. Walensky at the Dana Farber Cancer Institute. As an Assistant Professor of Pathology at Yale University, Dr. Katz manages a laboratory deciphering the basic mechanisms of cell death and contributes to patient care as an active hematopathologist.
Dr. Steven Kleinstein is a computational immunologist with a combination of "big data" analysis and immunology domain expertise. His research interests include both developing new computational methods and applying these methods to study human immune responses. Dr. Kleinstein received a B.A.S. in Computer Science from the University of Pennsylvania and a Ph.D. in Computer Science from Princeton University. He is currently an Associate Professor of Pathology (with a secondary appointment in Immunobiology) at the Yale School of Medicine, and a member of the Interdepartmental Program in Computational Biology and Bioinformatics (CBB), and the Human and Translational Immunology Program.
Specific areas of research focus include:
- High-throughput B cell receptor (BCR) repertoire profiling (AIRR-seq or Rep-seq)
- Immune signature of human infection and vaccination responses
Dr. Kyriakides completed a PhD at Washington State University in 1993. He did a postdoctoral fellowship at the University of Washington. His lab at Yale studies the molecular events that dictate the foreign body response to biomaterials. In addition, Dr. Kyriakides studies nanomaterials and cell interactions with a focus on biosensing. Finally, ongoing efforts in the lab include vascular engineering and engineering of tissue constructs to stimulate healing in diabetic wounds. He is Director of Graduate Studies for the Experimental Pathology PhD program. He also serves as a mentor for students from the School of Engineering and Applied Science.
- I am a graduate of Yale College (BA 1957), Oxford University (D.Phil.1961) and the Yale School of Medicine (MD, 1963). I trained in anatomical pathology at Washington University (1963-65), spent a post-doctoral year at Rockefeller University with George Palade, and served in the USPHS at the NIH from1966 to 1972.
I was recruited to Yale by Lewis Thomas in 1972, and a year later was named the Anthony N. Brady Professor of pathology and chair of the department and Pathologist-in-Chief of the Yale New Haven Hospital. In 1991 I became the Director of the Boyer Center for Molecular Medicine. I am a member of the National Academy of Sciences and the Institute of Medicine.
Wang Min, Ph.D., received his B.S. degree in Microbiology from Wuhan University in 1984, his M.S degree in Cell Biology at Shanghai Institute of Cell Biology, Chinese Academy of Sciences, in 1989, and his Ph.D degree in Genetics at University of Wales, Swansea, U.K., in 1993. He then performed 4-year post-doctoral training in vascular biology and immunology at the Department of Pathology, Yale School of Medicine. He became a Senior Scientist and Project Leader at GeneMedicine, Inc., in 1997 and then an Assistant Professor at University of Rochester, NY, in 1999. In 2003, he was recruited back to Department of Pathology and Vascular Biology Program at Yale School of Medicine, where he was promoted to Professor with Tenure in 2013. Dr. Min is a member of NAVBO, AHA, Yale Stem Cell Center and Yale Cancer Center. The goal in Dr. Min's lab is to dissect the signaling pathways, establish mouse models, and define the fundamental mechanisms involved in vascular development, remodeling, and repair related to human diseases such as vascular malformation, ischemia, and stroke. Dr. Min's lab has extensively employed biochemical, cell biological, and mouse genetic approaches to define the critical molecules mediating vascular development, remodeling, and repair. Dr. Min serves on the editorial board of Arteriosclerosis, Thrombosis, and Vascular Biology and Frontiers in Physiology. Dr. Min has been the recipient of many awards, including the Irvine H. Page Young Investigator Research Award, the AHA Established Investigator Award, the JACC Parmley Award, and CT Stem Cell EIA Award.
Dr. Moeckel graduated magna cum laude from Ludwig Maximillians University in Munich, Germany. He trained in anatomic and clinical pathology at the University of Arizona, Tucson, AZ and was on faculty in the Department of Pathology at Vanderbilt University, Nashville, TN prior to his recruitment as Director of the Renal Pathology and Electron Microscopy Laboratory at Yale University. His academic interests are in clinical renal pathology and research of mechanisms of kidney injury repair and progression of chronic kidney disease. Dr Moeckel is a fellow of the American Society of Nephrology and a Diplomat of the American Board of Pathology. He has published numerous papers in peer reviewed journals and has received private industry and federal grants to support his research.
- B.S., Microbiology and Immunology, McGill University, Montreal, Quebec, Canada. 1998.
- Ph.D., Microbiology and Immunology, University of Rochester, Rochester, NY. 2004
- Post-doctoral fellow, Cancer Biology and Genetics, Memorial Sloan-Kettering Institute, New York, NY. 2004-9.
Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus's lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as an Associate Professor in the Department of Pathology and the Yale Cancer Center.
David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is a member of the Executive Team in Pathology and serves as the Director of Translational Pathology. His lab group focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy or recurrence or metastasis in breast and lung cancer.The technology has also been used in a series of efforts related to biospecimen science. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH.He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP).He is an author of over 300 peer-reviewed papers and 8 patents.He has served on advisory boards for Amgen, Genentech, Novartis, BMS, Perkin Elmer, Dako, ACD, Biocept, OptraScan and Genoptix.He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.
Dr. Rose earned his Ph.D. at Stanford University in 1973 in the laboratory of Dr. Charles Yanofsky. His thesis research focused on regulation of the tryptophan operon of E. coli. He then did postdoctoral research at MIT in the laboratories of Drs. David Baltimore and Harvey Lodish, where he began work on eucaryotic RNA viruses. In 1978, Dr. Rose took a faculty position at the Salk Institute, where he continued work on RNA virus transcription, as well as structure, function, and transport of the vesicular stomatitis virus (VSV) glycoprotein. In 1986, he moved to become Professor of Pathology and Cell Biology at Yale University School of Medicine. In 1994, his laboratory developed a system for recovering non-segmented, negative-strand RNA viruses from DNA plasmids. His work at Yale during the past fifteen years has focused largely on new approaches to vaccine development using vectors based on recombinant VSV and other viral replicons. This work has led to development of robust vaccine platforms that can protect animals against numerous viral and bacterial pathogens, typically after a single dose. A VSV-based HIV vaccine advanced from the Rose laboratory has recently completed a successful Phase I clinical trial.
I trained as cell biologist, surgical pathologist and served in clinical molecular diagnostics. In addition, during my postdoctoral work at Yale I focused in developing strategies to objectively and quantitatively measure key immunotherapy related biomarkers in immune cells and cancer tissues. Most of this work has been performed in close collaboration with other Yale researchers and published in peer-reviewed journals. Recently, I was appointed to lead the Translational Immuno-Oncology Laboratory (T.I.L.) in the Yale Cancer Center, that aims to produce and support high quality translational research in immuno-oncology through standardized analyses of biomarkers and cross-integration with other Yale resources.
John Sinard is a board-certified anatomic pathologist. He received his bachelor's degree from Harvard University, and his M.D. and Ph.D. degrees from Johns Hopkins. His residency training was at Yale-New Haven Hospital. He is the Vice Chair of Pathology and Director of Anatomic Pathology and is active on the autopsy and surgical pathology services, with a specialty interest in ophthalmic pathology. He founded the Pathology Informatics Program, and has been developing software for over 30 years. His academic interests are centered on translational informatics: delivering modern data management tools to practicing physicians and researchers.
Jeffrey Sklar, M.D., Ph.D., received a B.A. in Biology from Haverford College, an M.D. from Yale School of Medicine, and a Ph.D. in Molecular Biophysics/Biochemistry from Yale University. He completed his residency in pathology at Stanford University Medical Center and his post-doctoral fellowship (in Biochemistry) at Stanford University.
He served as Assistant Professor and then Associate Professor of Pathology with tenure at Stanford University School of Medicine, 1981-89; then as Associate Professor and then Professor of Pathology at Harvard Medical School, 1989-2003. Currently, he is Professor of Pathology and Laboratory Medicine at Yale School of Medicine (2003-present).
Clinical interests: Molecular diagnostics.
Research Interests: Molecular biology of human disease, especially cancer; gene regulation; chromosome structure and chromosomal aberrations in human disease; trans-splicing of RNA; genetic predisposition to type 2 diabetes; immunogenetics.
The lab is presently particularly interested in two genes, JAZF1 and JJAZ1/SUZ12, which we discovered to be fused in the cells of certain uterine tumors. JJAZ1 is a Polycomb group gene, the product of which is essential for histone methylations that regulate chromatin remodeling and activity. We have investigated how the JAZF1-JJAZ1 fusion functions in oncogenesis and found that its action has features not previously described in cancer. Recently, we discovered that JAZF1-JJAZ1 RNA is produced by hormonally regulated trans-splicing between the pre-mRNAs for the two genes in normal endometrium. This discovery has led us to explore other examples of recombination between RNAs, which is much more common than previously thought. Relative to JJAZ1, little is known about the function of JAZF1, although single nucleotide polymorphisms in this gene are associated with altered risk for type 2 diabetes and prostate cancer. We are currently investigating the mechanisms of these associations.
Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van den Berghe H, Dal Cin P, Fletcher JA, Sklar J. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad of Sci USA 2001; 98: 6348-6353.
Li H, Ma X, Wang J, Koontz J, Nucci M, Sklar J. Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc Natl Acad Sci USA 2007; 104: 20001-20006.
Li H, Wang J, Mor G, Sklar J. A neoplastic gene fusion mimics trans-splicing of RNAs in normal cells. Science 2008; 321: 1357-1361.
Dr. Stern earned a BS in Biology at MIT in 1976. He received a PhD in Biology in 1983 at University of California, San Diego, and the Salk Institute with S.I.T. Kennedy and Bart Sefton for dissertation research that elucidated the coronavirus lytic cycle. Dr. Stern returned to R.A. Weinberg’s lab at the MIT Cancer Center and Whitehead Institute for Biomedical Research in 1983. There, Dr. Stern’s postdoctoral work pioneered analysis of neu/ErbB2/HER2, an important human oncogene. As a Yale Pathology faculty member since 1988, Dr. Stern’s research has focused on the roles of eleven growth factors and four receptors of the EGF family in malignant transformation, especially in breast cancer, and he has also made significant contributions to the understanding of DNA damage response signaling pathways. Dr. Stern’s current work in breast cancer and melanoma includes developing approaches to countering rapid resistance to anti-cancer agents that target cancer signaling pathways. Dr. Stern is active in cancer training at Yale and in the Yale Cancer Center scientific leadership. He is co-leader of the Signal Transduction Research Program and Associate Director of Shared Resources of the Yale Cancer Center.
Dr. Walther is a physician-scientist with clinical expertise in gastrointestinal and liver pathology, the molecular diagnostics of surgical pathology specimens, and molecular oncology of solid tumors. As Clinical Director of the YNHH Tumor Profiling Laboratory, she focuses on molecular and genomic analyses of solid tumor specimens, to enable the identification of therapeutic targets within individual patients' cancers, and thus to promote precision medicine in oncology.
Research Scientist and Associate Technical Director of Yale Molecular Diagnostics Laboratory.
ASCP board of certificate for Molecular Biologist Route 4.
Dr. Qin Yan （严钦) is an Associate Professor of Pathology at Yale Medical School and a member of Yale Comprehensive Cancer Center and Yale Stem Cell Center. He directs a research laboratory to elucidate the roles of epigenetic mechanisms that drive tumor initiation and progression and to translate the findings to the clinic. His laboratory has made significant contributions to the understanding of KDM5 H3K4me3/2 histone demethylases. Dr. Yan received his B.S. degree from the University of Science and Technology of China. After his Ph.D. training on regulation of transcription and ubiquitination with Drs. Joan and Ronald Conaway at the Oklahoma Medical Research Foundation and Stowers Institute for Medical Research, he completed his postdoctoral training on cancer biology with HHMI Investigator Dr. William Kaelin at the Dana-Farber Cancer Institute and Harvard Medical School. He has received numerous awards including Era of Hope Scholar Award from DoD Breast Cancer Research Program, Stewart Scholar Award and V Scholar Award.
Research experience: mouse knockout and transgenesis, molecular biology, enzymology, vascular biology, inflammation, angiogenesis, sepsis, macrophage.